medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 2

<< Back Next >>

Ann Hepatol 2018; 17 (2)

Fontan-Associated Liver Disease: A Review

Téllez L, Rodríguez-Santiago E, Albillos A

Language: English
References: 80
Page: 192-204
PDF size: 362.70 Kb.


ABSTRACT

Fontan-associated liver disease is a hepatic disorder arising from hemodynamic changes and systemic venous congestion following Fontan surgery. The histological changes produced in the liver are similar but not equivalent to those seen in other forms of cardiac liver disease. While the natural history of this form of liver disease is not well established, over time many Fontan patients develop portal hypertension-related complications such as ascites, variceal hemorrhage or encephalopathy. Fontan survivors also show an increased risk of hepatocellular carcinoma. Early diagnosis of advanced liver disease is mandatory for the prevention and treatment of complications such as hepatocellular carcinoma, esophageal varices and malnutrition. This review updates current knowledge of the pathophysiology and management of Fontan-associated liver disease including new diagnostic methods and treatments.


REFERENCES

  1. Gewillig M, Brown SC. The Fontan circulation after 45 years: update in physiology. Heart Br Card Soc 2016; 102: 1081-6.

  2. Quinton E, Nightingale P, Hudsmith L, Thorne S, Marshall H, Clift P, de Bono J, et al. Prevalence of atrial tachyarrhythmia in adults after Fontan operation. Heart Br Card Soc 2015; 101: 1672-7.

  3. Balaji S, Gewillig M, Bull C, de Leval MR, Deanfield JE. Arrhythmias after the Fontan procedure. Comparison of total cavopulmonary connection and atriopulmonary connection. Circulation 1991; 84: III162-7.

  4. Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax 1971; 26: 240-8.

  5. Allen KY, Downing TE, Glatz AC, Rogers LS, Ravishankar C, Rychik J, Fuller S, et al. Long-term survival after the Fontan operation: Twenty years of experience at a single center. J Thorac Cardiovasc Surg 2017; 154: 243-53.e2.

  6. Pundi KN, Johnson JN, Dearani JA, Pundi KN, Li Z, Hinck CA, Dahl SH, et al. 40-Year Follow-Up After the Fontan Operation: Long-Term Outcomes of 1,052 Patients. J Am Coll Cardiol 2015; 66: 1700-10.

  7. Ohuchi H. Adult patients with Fontan circulation: What we know and how to manage adults with Fontan circulation? J Cardiol 2016; 68: 181-9.

  8. Menon S, Chennapragada M, Ugaki S, Sholler GF, Ayer J, Winlaw DS. The Lymphatic Circulation in Adaptations to the Fontan Circulation. Pediatr Cardiol 2017; 38: 886-92.

  9. Ostrow AM, Freeze H, Rychik J. Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms. Ann Thorac Surg 2006; 82: 695-700.

  10. Heinemann M, Breuer J, Steger V, Steil E, Sieverding L, Ziemer G. Incidence and impact of systemic venous collateral development after Glenn and Fontan procedures. Thorac Cardiovasc Surg 2001; 49: 172-8.

  11. Anne P, Du W, Mattoo TK, Zilberman MV. Nephropathy in patients after Fontan palliation. Int J Cardiol 2009; 132: 244-7.

  12. Egbe AC, Connolly HM, Khan AR, Niaz T, Said SS, Dearani JA, Warnes CA, et al. Outcomes in adult Fontan patients with atrial tachyarrhythmias. Am Heart J 2017; 186: 12-20.

  13. Fernández-Iglesias A, Gracia-Sancho J. How to Face Chronic Liver Disease: The Sinusoidal Perspective. Front Med 2017; 4: 7.

  14. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet Lond Engl 2014; 383: 1749-61.

  15. Asrani SK, Asrani NS, Freese DK, Phillips SD, Warnes CA, Heimbach J, et al. Congenital heart disease and the liver. Hepatol Baltim Md 2012; 56: 1160-9.

  16. Greuter T, Shah VH. Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insights. J Gastroenterol 2016; 51: 511-9.

  17. Tomkiewicz-Pajak L, Hoffman P, Trojnarska O, Lipczynska M, Podolec P, Undas A. Abnormalities in blood coagulation, fibrinolysis, and platelet activation in adult patients after the Fontan procedure. J Thorac Cardiovasc Surg 2014; 147: 1284-90.

  18. Simonetto DA, Yang H, Yin M, de Assuncao TM, Kwon JH, Hilscher M, Pan S, et al. Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces. Hepatol Baltim Md 2015; 61: 648-59.

  19. Sung PS, Yoon SK. Amiodarone hepatotoxicity. Hepatol Baltim Md 2012; 55: 325-6.

  20. Wang A, Book WM, McConnell M, Lyle T, Rodby K, Mahle WT. Prevalence of hepatitis C infection in adult patients who underwent congenital heart surgery prior to screening in 1992. Am J Cardiol 2007; 100: 1307-9.

  21. Schwartz MC, Sullivan L, Cohen MS, Russo P, John AS, Guo R, Guttenberg M, et al. Hepatic pathology may develop before the Fontan operation in children with functional single ventricle: an autopsy study. J Thorac Cardiovasc Surg 2012; 143: 904-9.

  22. Johnson JA, Cetta F, Graham RP, Smyrk TC, Driscoll DJ, Phillips SD, John AS. Identifying predictors of hepatic disease in patients after the Fontan operation: a postmortem analysis. J Thorac Cardiovasc Surg 2013; 146: 140-5.

  23. Wu FM, Jonas MM, Opotowsky AR, Harmon A, Raza R, Ukomadu C, Landzberg MJ, et al. Portal and centrilobular hepatic fibrosis in Fontan circulation and clinical outcomes. J Heart Lung Transplant Off Publ Int Soc Heart Transplant 2015; 34: 883-91.

  24. Dichtl W, Vogel W, Dunst KM, Grander W, Alber HF, Frick M, Antretter H, et al. Cardiac hepatopathy before and after heart transplantation. Transpl Int Off J Eur Soc Organ Transplant 2005; 18: 697-702.

  25. Rychik J, Veldtman G, Rand E, Russo P, Rome JJ, Krok K, Goldberg DJ, et al. The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium. Pediatr Cardiol 2012; 33: 1001-12.

  26. Camposilvan S, Milanesi O, Stellin G, Pettenazzo A, Zancan L, D'Antiga L. Liver and cardiac function in the long term after Fontan operation. Ann Thorac Surg 2008; 86: 177-82.

  27. Mori M, Hebson C, Shioda K, Elder RW, Kogon BE, Rodriguez FH, Jokhadar M, et al. Catheter-measured Hemodynamics of Adult Fontan Circulation: Associations with Adverse Event and End-organ Dysfunctions. Congenit Heart Dis 2016; 11: 589-97.

  28. Kiesewetter CH, Sheron N, Vettukattill JJ, Hacking N, Stedman B, Millward-Sadler H, Haw M, et al. Hepatic changes in the failing Fontan circulation. Heart Br Card Soc 2007; 93: 579-84.

  29. Baek JS, Bae EJ, Ko JS, Kim GB, Kwon BS, Lee SY, Noh CI, et al. Late hepatic complications after Fontan operation; noninvasive markers of hepatic fibrosis and risk factors. Heart Br Card Soc 2010; 96: 1750-5.

  30. Pundi K, Pundi KN, Kamath PS, Cetta F, Li Z, Poterucha JT, Driscoll DJ, et al. Liver Disease in Patients After the Fontan Operation. Am J Cardiol 2016; 117: 456-60.

  31. Heuman DM, Mihas AA, Habib A, Gilles HS, Stravitz RT, Sanyal AJ, Fischer RA. MELD-XI: a rational approach to "sickest first" liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2007; 13: 30-7.

  32. Evans WN, Acherman RJ, Ciccolo ML, Carrillo SA, Galindo A, Rothman A, Mayman GA, et al. MELD-XI Scores Correlate with Post-Fontan Hepatic Biopsy Fibrosis Scores. Pediatr Cardiol 2016; 37: 1274-7.

  33. Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D. Severe liver fibrosis or cirrhosis: accuracy of US for de tection--analysis of 300 cases. Radiology 2003; 227: 89-94.

  34. Berzigotti A, Ashkenazi E, Reverter E, Abraldes JG, Bosch J. Non-invasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension. Dis Markers 2011; 31: 129-38.

  35. Giannini E, Botta F, Borro P, Risso D, Romagnoli P, Fasoli A, Mele MR, et al.. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 2003; 52: 1200-5.

  36. Bae JM, Jeon TY, Kim JS, Kim S, Hwang SM, Yoo SY, Kim JH. Fontan-associated liver disease: Spectrum of US findings. Eur J Radiol 2016; 85: 850-6.

  37. Kutty SS, Peng Q, Danford DA, Fletcher SE, Perry D, Talmon GA, Scott C, et al. Increased hepatic stiffness as consequence of high hepatic afterload in the Fontan circulation: a vascular Doppler and elastography study. Hepatol Baltim Md 2014; 59: 251-60.

  38. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-13.

  39. Caste’ra L, Foucher J, Bernard P-H, Carvalho F, Allaix D, Merrouche W, Couzigou P, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatol Baltim Md 2010; 51: 828-35.

  40. Deorsola L, Aidala E, Cascarano MT, Valori A, Agnoletti G, Pace Napoleone C. Liver stiffness modifications shortly after total cavopulmonary connection. Interact. Cardiovasc Thorac Surg 2016; 23: 513-8.

  41. Agnoletti G, Ferraro G, Bordese R, Marini D, Gala S, Bergamasco L, Ferroni F, et al. Fontan circulation causes early, severe liver damage. Should we offer patients a tailored strategy? Int J Cardiol 2016; 209: 60-5.

  42. Chen B, Schreiber RA, Human DG, Potts JE, Guttman OR. Assessment of Liver Stiffness in Pediatric Fontan Patients Using Transient Elastography. Can J Gastroenterol Hepatol 2016; 2016: 7125193.

  43. Bulut OP, Romero R, Mahle WT, McConnell M, Braithwaite K, Shehata BM, Gupta NA, et al. Magnetic resonance imaging identifies unsuspected liver abnormalities in patients after the Fontan procedure. J Pediatr 2013; 163: 201-6.

  44. Poterucha JT, Johnson JN, Qureshi MY, O’Leary PW, Kamath PS, Lennon RJ, Bonnichsen CR, et al. Magnetic Resonance Elastography: A Novel Technique for the Detection of Hepatic Fibrosis and Hepatocellular Carcinoma After the Fontan Operation. Mayo Clin Proc 2015; 90: 882-94.

  45. Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009; 6: 573-82.

  46. Bosch J, Abraldes JG, Albillos A, Aracil C, Bañares R, Berzigotti A, Calleja JL, et al. Hipertensión portal: recomendaciones para su evaluación y tratamiento. Gastroenterol Hepatol 2012; 35: 421-50.

  47. Kendall TJ, Stedman B, Hacking N, Haw M, Vettukattill JJ, Salmon AP, Cope R, et al. Hepatic fibrosis and cirrhosis in the Fontan circulation: a detailed morphological study. J Clin Pathol 2008; 61: 504-8.

  48. Goldberg DJ, Surrey LF, Glatz AC, Dodds K, O’Byrne ML, Lin HC, Fogel M, et al. Hepatic Fibrosis Is Universal Following Fontan Operation, and Severity is Associated With Time From Surgery: A Liver Biopsy and Hemodynamic Study. J Am Heart Assoc 2017; 6. J Am Heart Assoc. 2017 Apr 26;6(5). pii: e004809. doi: 10.1161/JAHA.116.004809.

  49. D’Souza BA, Fuller S, Gleason LP, Hornsby N, Wald J, Krok K, Shanked A, et al. Single-center outcomes of combined heart and liver transplantation in the failing Fontan. Clin Transplant 2017; 31. doi: 10.1111/ctr.12892. Epub 2017 Feb 4.

  50. Ford RM, Book W, Spivey JR. Liver disease related to the heart. Transplant Rev Orlando Fla 2015; 29: 33-7.

  51. Wu FM, Kogon B, Earing MG, Aboulhosn JA, Broberg CS, John AS Harmon A, et al. Liver health in adults with Fontan circulation: A multicenter cross-sectional study. J Thorac Cardiovasc Surg 2017; 153: 656-64.

  52. Wallihan DB, Podberesky DJ. Hepatic pathology after Fontan palliation: spectrum of imaging findings. Pediatr Radiol 2013; 43: 330-8.

  53. Shimamatsu K, Wanless IR. Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver. Hepatol Baltim Md 1997; 26: 343-50.

  54. Ghaferi AA, Hutchins GM. Progression of liver pathology in patients undergoing the Fontan procedure: Chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg 2005; 129: 1348-52.

  55. Saliba T, Dorkhom S, O'Reilly EM, Ludwig E, Gansukh B, Abou-Alfa GK. Hepatocellular carcinoma in two patients with cardiac cirrhosis. Eur J Gastroenterol Hepatol 2010; 22: 889-91.

  56. Asrani SK, Warnes CA, Kamath PS. Hepatocellular carcinoma after the Fontan procedure. N Engl J Med 2013; 368: 1756-7.

  57. Elder RW, Parekh S, Book WM. More on hepatocellular carcinoma after the Fontan procedure. N Engl J Med 2013; 369: 490.

  58. Takuma Y, Fukada Y, Iwadou S, Miyatake H, Uematsu S, Okamoto R, Sato D, et al. Surgical Resection for Hepatocellular Carcinoma with Cardiac Cirrhosis after the Fontan Procedure. Intern. Med Tokyo Jpn 2016; 55: 3265-72.

  59. Rajoriya N, Clift P, Thorne S, Hirschfield GM, Ferguson JW. A liver mass post-Fontan operation. QJM Mon J Assoc Physicians 2014; 107: 571-2.

  60. Weyker PD, Allen-John Webb C, Emond JC, Brentjens TE, Johnston TA. Anesthetic implications of extended right hepatectomy in a patient with Fontan physiology. Case Rep 2014; 2: 99-101.

  61. Kwon S, Scovel L, Yeh M, Dorsey D, Dembo G, Krieger EV, Bakthavatsalam R, et al. Surgical management of hepatocellular carcinoma after Fontan procedure. J Gastrointest Oncol 2015; 6: E55-60.

  62. Yamada K, Shinmoto H, Kawamura Y, Wakamatsu H, Kawauchi T, Soga S, Soga S, et al. Transarterial embolization for pediatric hepatocellular carcinoma with cardiac cirrhosis. Pediatr. Int Off J Jpn Pediatr Soc 2015; 57: 766-70.

  63. Oh C, Youn JK, Han J-W, Kim GB, Kim H-Y, Jung S-E. Hepatocellular carcinoma after the Fontan procedure in a 16-yearold girl: A case report. Medicine (Baltimore) 2016; 95: e4823.

  64. Conroy MR, Moe TG. Hepatocellular carcinoma in the adult Fontan patient. Cardiol Young 2017; 27: 407-9.

  65. Josephus Jitta D, Wagenaar LJ, Mulder BJM, Guichelaar M, Bouman D, van Melle JP. Three cases of hepatocellular carcinoma in Fontan patients: Review of the literature and suggestions for hepatic screening. Int J Cardiol 2016; 206: 21-6.

  66. Martínez-Quintana E, Monescillo A, Rodríguez-González F. Hepatocellular carcinoma in a non-failing Fontan circulation. Rev Española Enfermedades Dig Organo Of Soc Española Patol Dig 2017; 109: 375.

  67. Nandwana SB, Olaiya B, Cox K, Sahu A, Mittal P. Abdominal Imaging Surveillance in Adult Patients After Fontan Procedure: Risk of Chronic Liver Disease and Hepatocellular Carcinoma. Curr Probl Diagn Radiol 2017; 2018 Jan - Feb;47(1):19-22..

  68. Forner A, Reig M, Varela M, Burrel M, Feliu J, Bricen~o J, Sastre J, et al. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016; 146: 511.e1-511.e22.

  69. Koteda Y, Suda K, Kishimoto S, Iemura M. Portal-systemic encephalopathy after Fontan-type operation in patient with polysplenia syndrome. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg 2009; 35: 1083-5.

  70. Elder RW, McCabe NM, Hebson C, Veledar E, Romero R, Ford RM, (Missing author) et al. Features of portal hypertension are associated with major adverse events in Fontan patients: the VAST study. Int J Cardiol 2013; 168: 3764-9.

  71. de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63: 743-52.

  72. Velpula M, Sheron N, Guha N, Salmon T, Hacking N, Veldtman GR. Direct measurement of porto-systemic gradient in a failing Fontan circulation. Congenit Heart Dis 2011; 6: 175-8.

  73. Pericleous M, Sarnowski A, Moore A, Fijten R, Zaman M. The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations. Eur J Gastroenterol Hepatol 2016; 28: e10-18.

  74. Myers RP, Cerini R, Sayegh R, Moreau R, Degott C, Lebrec D, Lee SS. Cardiac hepatopathy: Clinical, hemodynamic, and histologic characteristics and correlations. Hepatology 2003; 37: 393-400.

  75. Hilscher MB, Johnson JN, Cetta F, Driscoll DJ, Poterucha JJ, Sanchez W, Connolly HM, et al. Surveillance for liver complications after the Fontan procedure. Congenit Heart Dis 2017; 12: 124-32.

  76. American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol 2014; 61: 642-59.

  77. Zoubek ME, Trautwein C, Strnad P. Reversal of liver fibrosis: From fiction to reality. Best Pract Res Clin Gastroenterol 2017; 31: 129-41.

  78. Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol 2012; 56: 1171-80.

  79. Dichtl W, Vogel W, Dunst KM, Grander W, Alber HF, Frick M, Antretter H, et al. Cardiac hepatopathy before and after heart transplantation. Transpl Int Off J Eur Soc Organ Transplant 2005; 18: 697-702.

  80. Crespo-Leiro MG, Robles O, Paniagua MJ, Marzoa R, Naya C, Flores X, Naya C, et al. Reversal of cardiac cirrhosis following orthotopic heart transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 2008; 8: 1336-9.




2020     |     www.medigraphic.com